Tags Archive Navigation
icon
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
-
Media ReleaseNovartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
-
Media ReleaseNovartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
-
Media ReleaseNovartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
-
Media ReleaseNovartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia
-
Media ReleaseNovartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
-
Media ReleaseNovartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
-
Media ReleaseNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
-
Media ReleaseNovartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
-
Media ReleaseNovartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- › Next page